Back to Search
Start Over
Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders
- Source :
- Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
- Publication Year :
- 2016
- Publisher :
- BMJ Publishing Group, 2016.
-
Abstract
- The T-cell lymphoproliferative disorders are a heterogeneous group of non-Hodgkin’s lymphomas (NHL) for which current therapeutic strategies are inadequate, as most patients afflicted with these NHL will succumb to disease progression within 2 years of diagnosis. Appreciation of the genetic and immunologic landscape of these aggressive NHL, including PD-L1 (B7-H1, CD274) expression by malignant T cells and within the tumor microenvironment, provides a strong rationale for therapeutic targeting this immune checkpoint. While further studies are needed, the available data suggests that responses with PD-1 checkpoint blockade alone will unlikely approach those achieved in other lymphoproliferative disorders. Herein, we review the unique challenges posed by the T-cell lymphoproliferative disorders and discuss potential strategies to optimize checkpoint blockade in these T-cell derived malignancies.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 4
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Journal for ImmunoTherapy of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.32ced5c385b49be9f53c5ca0aa78931
- Document Type :
- article
- Full Text :
- https://doi.org/10.1186/s40425-016-0201-6